t
Oxford Biomedica PLC held its Annual General Meeting on May 7, 2026, where all 17 proposed resolutions were duly passed by poll vote. These resolutions included the adoption of the Annual Report, reappointment of nine directors, reappointment of PricewaterhouseCoopers LLP as auditors, and authorization for share allotment and disapplication of pre-emption rights. On the record date of May 5, 2026, there were 120,920,518 ordinary shares in issue, with votes for resolutions ranging from 85.24 million (96.78%) to 88.05 million (99.98%) of total votes cast.
| Date | 7 May 2026 |
| Time | 16:58:16 |
| Category | AGMs and other meetings |
| ID | 4909D |
OXB
Result of Annual General Meeting
Oxford, UK - 07 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that all proposed resolutions were duly passed at its Annual General Meeting ("AGM"), held at 3 pm on 07 May 2026 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.
The full text of all the resolutions can be viewed in the Notice of AGM by visiting the Company's website at www.oxb.com
Copies of the document setting out the above resolutions passed at the 2026 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (05 May 2026) there were 120,920,518 ordinary shares of 50 pence each in issue, each carrying one vote per share.
|
|
Resolutions |
Votes For (incl. votes at the Chair's discretion) |
% of votes cast |
Votes Against |
% of votes cast |
Votes Withheld* |
Total votes cast** |
Result |
|
|
Ordinary resolutions |
|
|
|
|
|
|
|
|
1 |
To receive and adopt the Company's Annual Report and accounts for the financial year ended 31 December 2025, the Directors' Report, and the Report of the Independent Auditors on those accounts and reports. |
88,022,096 |
99.98% |
14,253 |
0.02% |
149,975 |
88,036,349 |
PASS |
|
2 |
To receive the Directors' Remuneration Report and the Report of the Independent Auditors on the auditable part of the Remuneration Report (excluding the Directors' Remuneration Policy) set out at pages 90 to 112 of the Annual Report for the financial year ended 31 December 2025. |
77,910,043 |
88.51% |
10,114,321 |
11.49% |
161,960 |
88,024,364 |
PASS |
|
3 |
To reappoint Dr. Roch Doliveux as a Director of the Company. |
85,639,916 |
97.24% |
2,431,539 |
2.76% |
114,869 |
88,071,455 |
PASS |
|
4 |
To reappoint Dr. Frank Mathias as a Director of the Company. |
86,374,661 |
98.07% |
1,696,798 |
1.93% |
114,865 |
88,071,459 |
PASS |
|
5 |
To reappoint Peter Soelkner as a Director of the Company. |
85,669,982 |
97.27% |
2,401,339 |
2.73% |
115,003 |
88,071,321 |
PASS |
|
6 |
To reappoint Professor Dame Kay Davies as a Director of the Company. |
85,671,463 |
97.28% |
2,399,858 |
2.72% |
115,003 |
88,071,321 |
PASS |
|
7 |
To reappoint Colin Bond as a Director of the Company. |
87,273,801 |
99.09% |
797,520 |
0.91% |
115,003 |
88,071,321 |
PASS |
|
8 |
To reappoint Dr. Lucinda Crabtree as a Director of the Company. |
88,047,431 |
99.97% |
24,028 |
0.03% |
114,865 |
88,071,459 |
PASS |
|
9 |
To reappoint Laurence Espinasse as a Director of the Company. |
88,046,231 |
99.97% |
25,093 |
0.03% |
115,000 |
88,071,324 |
PASS |
|
10 |
To reappoint Namrata Patel as a Director of the Company. |
88,045,714 |
99.97% |
25,610 |
0.03% |
115,000 |
88,071,324 |
PASS |
|
11
|
To reappoint Dr. Heather Preston as a Director of the Company. |
85,236,452 |
96.78% |
2,834,872 |
3.22% |
115,000 |
88,071,324 |
PASS |
|
12 |
To reappoint PricewaterhouseCoopers LLP as auditors of the Company from the conclusion of the 2026 AGM until the conclusion of the next AGM of the Company at which the accounts are laid. |
88,052,667 |
99.98% |
17,899 |
0.02% |
115,758 |
88,070,566 |
PASS |
|
13 |
To authorise the Audit Committee for and on behalf of the Board to determine the auditors' remuneration. |
88,054,882 |
99.98% |
16,778 |
0.02% |
114,664 |
88,071,660 |
PASS |
|
14 |
To authorise the Directors to allot shares. |
87,589,834 |
99.46% |
478,537 |
0.54% |
117,953 |
88,068,371 |
PASS |
|
|
Special resolutions |
|
|
|
|
|
|
|
|
15 |
To authorise the Directors to disapply pre-emption rights. |
87,247,698 |
99.07% |
819,891 |
0.93% |
118,735 |
88,067,589 |
PASS |
|
16 |
To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments. |
87,103,359 |
98.90% |
968,950 |
1.10% |
114,015 |
88,072,309 |
PASS |
|
17 |
To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice. |
87,482,967 |
99.33% |
590,744 |
0.67% |
112,613 |
88,073,711 |
PASS |
* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.
** Total does not include withheld votes.
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: [email protected]
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: [email protected]
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE 250 and a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.